In 2000, an extensive consultation  was carried out on behalf of the European Commission to review the operation of the new European System since 1995. It has revealed that there is a broad level of satisfaction about the system from ministries, patient and professional associations, regulatory authorities, and industry, although improvements can be made and new challenges exist.
There is a general feeling that the system has contributed to the creation of a harmonized EU market for medicinal products and that it provides a strong foundation for an efficient regulatory environment. There is also a general perception that assessment of products to date has provided a high degree of protection to the public health. This is despite the fact that there have been withdrawals from the market of products already authorized. This is considered consistent with increasingly effective pharmacovigilance procedures and the bias toward products developed on the leading edge of science.
Was this article helpful?